Gynecologic Oncology Reports最新文献

筛选
英文 中文
Scrolling surgeons: Assessment of social media and artificial intelligence usage in gynecologic oncology fellows and fellowship programs 滚动外科医生:评估社交媒体和人工智能在妇科肿瘤研究员和奖学金项目中的使用
IF 1.3
Gynecologic Oncology Reports Pub Date : 2025-08-18 DOI: 10.1016/j.gore.2025.101923
Jessica Sciuva , Ivana DeVengencie , Jessica Fulton , Molly Morton , Julia Chalif , Eric Rios-Doria , Laura M. Chambers
{"title":"Scrolling surgeons: Assessment of social media and artificial intelligence usage in gynecologic oncology fellows and fellowship programs","authors":"Jessica Sciuva ,&nbsp;Ivana DeVengencie ,&nbsp;Jessica Fulton ,&nbsp;Molly Morton ,&nbsp;Julia Chalif ,&nbsp;Eric Rios-Doria ,&nbsp;Laura M. Chambers","doi":"10.1016/j.gore.2025.101923","DOIUrl":"10.1016/j.gore.2025.101923","url":null,"abstract":"<div><h3>Objectives</h3><div>This study examines gynecologic oncology fellows’ perceptions and use of social media and artificial intelligence (AI) and their perception of virtual fellowship interviews.</div></div><div><h3>Methods</h3><div>A cross-sectional, IRB-approved survey was distributed to fellows enrolled in ACGME-accredited gynecologic oncology programs across the United States in December 2023. The survey collected demographic data and assessed social media engagement, AI utilization, and perceptions of their applicability in clinical, educational, and professional settings.</div></div><div><h3>Results</h3><div>A total of 36 gynecologic oncology fellows participated. The majority reported using social media for personal purposes (62.5 % strongly agreed, 25.0 % agreed). However, 43.8 % agreed that they used social media for educational purposes, and a significant proportion (43.8 % disagreed, 25.0 % strongly disagreed) did not use social media to promote professional achievements. Most fellows recognized social media’s role in patient engagement (50.0 % strongly agreed, 43.8 % agreed) and expressed a desire for more reliable patient-directed content (93.8 % strongly agreed or agreed). While 59.4 % believed social media was useful for fellowship recruitment, it had minimal impact on rank list decisions. Regarding AI, 53.1 % reported using AI tools such as ChatGPT for research (64.7 %) and professional writing (35.3 %), with limited use in patient care. Many fellows (47.1 % strongly agreed, 29.4 % agreed) expressed interest in formal AI training.</div></div><div><h3>Conclusions</h3><div>Gynecologic oncology fellows primarily use social media for personal rather than professional purposes. AI is emerging as a research tool, though concerns persist regarding its application in patient care. Formal training in social media and AI could enhance fellows’ ability to integrate these tools practice.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"61 ","pages":"Article 101923"},"PeriodicalIF":1.3,"publicationDate":"2025-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144903729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Take it or leave it? Incidental appendectomy at time of gynecologic oncology laparotomy 接受还是放弃?妇科肿瘤剖腹手术时的意外阑尾切除术
IF 1.3
Gynecologic Oncology Reports Pub Date : 2025-08-18 DOI: 10.1016/j.gore.2025.101926
Nora Badiner , Angela Mirzadeh , Lauren Sword , Mary Herberger , Hayley Butler , Ruofan Yao , Yevgeniya Ioffe , Linda Hong
{"title":"Take it or leave it? Incidental appendectomy at time of gynecologic oncology laparotomy","authors":"Nora Badiner ,&nbsp;Angela Mirzadeh ,&nbsp;Lauren Sword ,&nbsp;Mary Herberger ,&nbsp;Hayley Butler ,&nbsp;Ruofan Yao ,&nbsp;Yevgeniya Ioffe ,&nbsp;Linda Hong","doi":"10.1016/j.gore.2025.101926","DOIUrl":"10.1016/j.gore.2025.101926","url":null,"abstract":"<div><h3>Objective</h3><div>The role of appendectomy in gynecologic oncology surgery has primarily been studied in mucinous ovarian pathologies. We sought to assess the safety and potential benefits of performing incidental appendectomy at time of exploratory laparotomy performed by gynecologic oncologists.</div></div><div><h3>Methods</h3><div>Retrospective chart review of patients undergoing exploratory laparotomy with the gynecologic oncology division. Exclusion criteria included cesarean hysterectomy and reoperation. Patients were matched on BMI, procedure date and type. 513 patients were identified for inclusion: 169 patients underwent appendectomy and 344 patients did not. Demographic and clinical characteristics were abstracted from the electronic medical record. Appendiceal appearance was confirmed via pathology report. Safety outcomes included length of hospital stay and postoperative complications.</div></div><div><h3>Results</h3><div>The two groups were demographically similar. There was no significant difference in length of hospital stay between the cohorts (6.10 ± 5.34 days vs. 5.87 ± 5.34 days, P = 0.645) and no increased rate of any of the postoperative complications in the appendectomy group. 119 patients (70.4 %) had abnormal appendixes intraoperatively. Among normal appendixes, six (12 %) had an occult finding only diagnosed on final pathology. No patients with apparent pelvic-confined gynecologic cancer were upstaged solely due to metastasis to the appendix.</div></div><div><h3>Conclusions</h3><div>When performed by a gynecologic oncologist, appendectomy at the time of laparotomy was safe and did not increase the risk of complications. Our results demonstrate a high rate of occult abnormal histology despite a normal intraoperative appearance. These findings suggest that intraoperative appearance alone is not sufficient, and support performing incidental appendectomy at the time of gynecologic oncology exploratory laparotomy.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"61 ","pages":"Article 101926"},"PeriodicalIF":1.3,"publicationDate":"2025-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144863236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Fertility preservation in patients with ovarian tumours - a single centre experience. 卵巢肿瘤患者的生育能力保存-单一中心经验。
IF 1.3
Gynecologic Oncology Reports Pub Date : 2025-08-05 eCollection Date: 2025-08-01 DOI: 10.1016/j.gore.2025.101918
Alexandra Almeida-Santos, Cristina Frutuoso, Teresa Almeida-Santos
{"title":"Fertility preservation in patients with ovarian tumours - a single centre experience.","authors":"Alexandra Almeida-Santos, Cristina Frutuoso, Teresa Almeida-Santos","doi":"10.1016/j.gore.2025.101918","DOIUrl":"10.1016/j.gore.2025.101918","url":null,"abstract":"<p><strong>Objective: </strong>A report of the 15 years'-experience in fertility preservation in women with ovarian tumours, at the Fertility Preservation Centre of the <i>Unidade Local de Saúde</i> Coimbra, the only Centre in Portugal performing fertility preservation techniques in pre-pubertal patients.</p><p><strong>Methods: </strong>A retrospective analysis of our centre database was made, including pre-pubertal and fertile-aged female patients diagnosed with ovarian tumours referred to a Fertility Preservation appointment from January 2009 to January 2024.</p><p><strong>Results: </strong>Twenty-one patients were referred for a fertility preservation appointment and 62 % had oocytes or ovarian tissue cryopreserved, seven of them after tumour recurrence. Six women had their oocytes cryopreserved and despite the site of the tumour, we achieved a medium oocyte yield of five oocytes in metaphase II. One patient has already used her frozen oocytes, but embryo development arrested before transfer. The youngest patient in whom ovarian tissue was frozen was a 4-months' old infant. Ovarian tissue thawing and transplantation was already done in two patients of 31 and 35 years old, but function was not restored. No live births were registered so far.</p><p><strong>Conclusion: </strong>Fertility preservation options should be offered to every woman with an ovarian tumour before oncological treatment, considering the ongoing research in this field. Further monitoring is needed to better evaluate both recurrence-risks and live births' rates.</p>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"60 ","pages":"101918"},"PeriodicalIF":1.3,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12355917/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144872829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Growing teratoma syndrome in a chemotherapy naïve patient 化疗患者的生长畸胎瘤综合征naïve
IF 1.3
Gynecologic Oncology Reports Pub Date : 2025-08-01 DOI: 10.1016/j.gore.2025.101815
Sarah Werner , Tricia Numan , Peter Frederick , Nicole Gaulin , Katherine Mager , Mohamed Desouki , Emese Zsiros
{"title":"Growing teratoma syndrome in a chemotherapy naïve patient","authors":"Sarah Werner ,&nbsp;Tricia Numan ,&nbsp;Peter Frederick ,&nbsp;Nicole Gaulin ,&nbsp;Katherine Mager ,&nbsp;Mohamed Desouki ,&nbsp;Emese Zsiros","doi":"10.1016/j.gore.2025.101815","DOIUrl":"10.1016/j.gore.2025.101815","url":null,"abstract":"<div><div>Growing Teratoma Syndrome (GTS) is an exceptionally rare condition primarily observed in patients diagnosed with malignant germ cell tumors. It is characterized by the development of enlarging masses during or following the completion of appropriate chemotherapy, with normalization of previously elevated serum tumor markers, and a final pathologic assessment of the masses reveals benign mature teratomatous elements. The underlying mechanism of the benign teratomatous growth remains unclear. Multiple potential routes of dissemination have been proposed, with the peritoneum being the most reported site of metastasis.</div><div>In this report, we present the case of an adolescent female patient diagnosed with an ovarian grade 1 immature teratoma, who developed disseminated peritoneal and mesenteric implants shortly after her initial surgery. The pathologic review of the implants demonstrated only mature teratomatous elements. Uniquely, the masses were identified in a chemotherapy naïve patient.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"60 ","pages":"Article 101815"},"PeriodicalIF":1.3,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144780598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Real-world outcomes after pembrolizumab treatment for cervical cancer: Results from a university setting 派姆单抗治疗宫颈癌后的真实结果:来自大学环境的结果
IF 1.3
Gynecologic Oncology Reports Pub Date : 2025-08-01 DOI: 10.1016/j.gore.2025.101921
Rachel L. Furuya , Katelin Boak , Mary M. Mullen , Dong Wang , L. Stewart Massad
{"title":"Real-world outcomes after pembrolizumab treatment for cervical cancer: Results from a university setting","authors":"Rachel L. Furuya ,&nbsp;Katelin Boak ,&nbsp;Mary M. Mullen ,&nbsp;Dong Wang ,&nbsp;L. Stewart Massad","doi":"10.1016/j.gore.2025.101921","DOIUrl":"10.1016/j.gore.2025.101921","url":null,"abstract":"<div><h3>Objective</h3><div>To estimate survival among patients with cervical cancer treated with pembrolizumab, examine risk factors for poor outcomes, and assess toxicities in a real-world setting.</div></div><div><h3>Methods</h3><div>This retrospective study included patients treated with pembrolizumab for advanced or recurrent cervical cancer at a tertiary academic center. Data were collected from patients initiating pembrolizumab treatment after May 2018 through June 2023. Overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan-Meier method. Associations between patient characteristics and OS were assessed using a Cox model.</div></div><div><h3>Results</h3><div>Forty-four patients were included in the study. Mean age at first pembrolizumab was 51.4 years and 30 % of patients self-identified as non-White. Complete response was seen in 10 patients (23 %). Median OS was 47.5 months (95 % confidence interval (CI), 19.7 to not estimable) and median PFS was 9.1 months (95 % CI, 7.4 to 15.8). Patients with Eastern Cooperative Oncology Group Performance Status (PS) &gt; 1 had a six-fold increased hazard of death compared to PS of 0 or 1 (p =0.0038). Five patients with a PS &gt; 1. Four died of disease progression; one was alive at last follow-up. A total of 22 adverse events occurred, and 7 % were grade 3 or higher.</div></div><div><h3>Conclusion</h3><div>Pembrolizumab is safe and effective for advanced and recurrent cervical cancer in a real-world population. For those with good performance, further study is needed to determine if prolonged complete responses are cures. PS should be considered when making treatment recommendations, as patients with poor PS may not experience the survival benefits shown in pivotal trials.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"60 ","pages":"Article 101921"},"PeriodicalIF":1.3,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144826566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of lymph node staging techniques on lymphedema and quality of life in early-stage endometrial cancer: A prospective cohort study 淋巴结分期技术对早期子宫内膜癌淋巴水肿和生活质量的影响:一项前瞻性队列研究
IF 1.3
Gynecologic Oncology Reports Pub Date : 2025-08-01 DOI: 10.1016/j.gore.2025.101919
Anna Torrent , Joana Amengual , Angela Ruiz , Aina Serra , Laura Fuertes , Catalina Maria Sampol , Mario Ruiz , Jorge Rioja , Pilar Roca , Octavi Cordoba
{"title":"Impact of lymph node staging techniques on lymphedema and quality of life in early-stage endometrial cancer: A prospective cohort study","authors":"Anna Torrent ,&nbsp;Joana Amengual ,&nbsp;Angela Ruiz ,&nbsp;Aina Serra ,&nbsp;Laura Fuertes ,&nbsp;Catalina Maria Sampol ,&nbsp;Mario Ruiz ,&nbsp;Jorge Rioja ,&nbsp;Pilar Roca ,&nbsp;Octavi Cordoba","doi":"10.1016/j.gore.2025.101919","DOIUrl":"10.1016/j.gore.2025.101919","url":null,"abstract":"<div><h3>Background</h3><div>Sentinel lymph node (SLN) biopsy is increasingly replacing complete pelvic lymphadenectomy (CL) for staging early-stage endometrial cancer (EC), but its long-term impact on patients’ quality of life (QoL) and lymphedema remains underexplored.</div></div><div><h3>Objective</h3><div>To compare overall health perception (oHP), health-related QoL (HRQoL), and symptomatic lymphedema in patients staged with SLN versus CL. Secondary objectives included the assessment of symptomatic lymphedema and surgical complications.</div></div><div><h3>Methods</h3><div>We conducted a prospective single-center observational study including 97 patients treated early-stage EC, with 50 undergoing SLN plus CL and 47 undergoing SLN only. Patients completed EQ-5D-3L, oHP scale (0–100), and the self-reported lower-extremity lymphedema questionnaire (LELQ) at baseline and 6-month follow-up. Multivariate analysis adjusted for confounders including surgical approach and adjuvant therapy.</div></div><div><h3>Results</h3><div>At 6 months, the SLN group reported significantly better oHP (median 85 vs. 70; p = 0.001) and HRQoL impairment (median score 5 vs. 7; p = 0.001) than the CL group. Symptomatic lymphedema (LELQ &gt; 5) was significantly lower in the SLN group (7.0 %) than in the CL group (34.4 %, p = 0.002). No significant differences in intra- or postoperative complications were observed.</div></div><div><h3>Conclusion</h3><div>SLN biopsy was associated with improved QoL and lower incidence of lymphedema compared to complete lymphadenectomy. These findings support the use of SLN mapping as the preferred nodal staging technique to minimize morbidity and enhance survivorship outcomes in early-stage EC patients.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"60 ","pages":"Article 101919"},"PeriodicalIF":1.3,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144766761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ivermectin treatment for gynecologic cancers—Hope versus hype 伊维菌素治疗妇科癌症:希望还是炒作
IF 1.3
Gynecologic Oncology Reports Pub Date : 2025-08-01 DOI: 10.1016/j.gore.2025.101920
J.Michael Straughn Jr.
{"title":"Ivermectin treatment for gynecologic cancers—Hope versus hype","authors":"J.Michael Straughn Jr.","doi":"10.1016/j.gore.2025.101920","DOIUrl":"10.1016/j.gore.2025.101920","url":null,"abstract":"","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"60 ","pages":"Article 101920"},"PeriodicalIF":1.3,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144864339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Risk factors for delayed diagnosis of endometrial cancer among black individuals: Results from the GUIDE-EC study 黑人子宫内膜癌延迟诊断的危险因素:GUIDE-EC研究结果
IF 1.3
Gynecologic Oncology Reports Pub Date : 2025-08-01 DOI: 10.1016/j.gore.2025.101922
Maya E. Gross , Mindy Pike , Julianna Alson , Patrice Williams , Mollie E. Wood , Erica Marsh , Erin Carey , Til Stürmer , Ronit Katz , Whitney R. Robinson , Kemi M. Doll
{"title":"Risk factors for delayed diagnosis of endometrial cancer among black individuals: Results from the GUIDE-EC study","authors":"Maya E. Gross ,&nbsp;Mindy Pike ,&nbsp;Julianna Alson ,&nbsp;Patrice Williams ,&nbsp;Mollie E. Wood ,&nbsp;Erica Marsh ,&nbsp;Erin Carey ,&nbsp;Til Stürmer ,&nbsp;Ronit Katz ,&nbsp;Whitney R. Robinson ,&nbsp;Kemi M. Doll","doi":"10.1016/j.gore.2025.101922","DOIUrl":"10.1016/j.gore.2025.101922","url":null,"abstract":"<div><h3>Objective</h3><div>Black patients with endometrial cancer (EC) experience disproportionately advanced stage at diagnosis. We aimed to identify variables, beyond race and histologic subtype, which increase risk for delayed diagnosis of EC.</div></div><div><h3>Methods</h3><div>This is a retrospective study of Black individuals with EC in a large academic-affiliated healthcare system from 2014 to 2020. Primary outcome was delayed diagnosis of EC, defined as prolonged time to diagnosis (&gt;28 days to reach diagnosis). We used descriptive statistics, univariate regression, and factor analysis to identify variables associated with delayed diagnosis, achieve data reduction, and calculate odds ratios for delayed diagnosis.</div></div><div><h3>Results</h3><div>Of 388 patients with EC included for analysis, one fifth (n = 79, 20 %) experienced delayed diagnosis. Ultrasound had the strongest association with delayed diagnosis in univariate regression (OR 4.4, 95 % CI 2.4, 7.8) and factor analysis (OR 2.2, 95 % CI 1.6, 3.0). BMI ≥ 40 (OR 1.9, 95 % CI 1.1, 3.3) was also associated with delayed diagnosis. Age ≥ 50 was associated with decreased odds of delayed diagnosis (OR 0.3, 95 % CI 0.2, 0.7). Presence of an endometrial biopsy was associated with decreased odds of delayed diagnosis on univariate regression (OR 0.4, 95 % CI 0.2, 1.4).</div></div><div><h3>Conclusions</h3><div>A fifth of Black patients with EC experienced delayed diagnosis, and preoperative ultrasound was most strongly associated with delayed diagnosis. Providers should consider a tissue-sampling-first approach in Black patients at risk for EC.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"60 ","pages":"Article 101922"},"PeriodicalIF":1.3,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144826563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pembrolizumab-associated Guillain-Barre syndrome in a patient with endometrial cancer: A case report 子宫内膜癌患者的派姆单抗相关格林-巴利综合征1例报告
IF 1.3
Gynecologic Oncology Reports Pub Date : 2025-08-01 DOI: 10.1016/j.gore.2025.101816
Emily Gleason , Meridith Pollie , Sanjana Satish , Sue Li , Janos L. Tanyi
{"title":"Pembrolizumab-associated Guillain-Barre syndrome in a patient with endometrial cancer: A case report","authors":"Emily Gleason ,&nbsp;Meridith Pollie ,&nbsp;Sanjana Satish ,&nbsp;Sue Li ,&nbsp;Janos L. Tanyi","doi":"10.1016/j.gore.2025.101816","DOIUrl":"10.1016/j.gore.2025.101816","url":null,"abstract":"<div><h3>Objective</h3><div>Guillain–Barré syndrome (GBS) is a rare yet potentially life-threatening adverse event of immune checkpoint inhibitors (ICI). It classically presents with ascending symmetric weakness, areflexia, and distal sensory loss. We present a case of pembrolizumab-induced GBS in a patient with advanced endometrial cancer.</div></div><div><h3>Methods</h3><div>All information was obtained via chart review with patient consent.</div></div><div><h3>Results</h3><div>A 77-year-old female with stage IIIC1 grade 3 endometrioid endometrial cancer received received carboplatin, paclitaxel, and pembrolizumab. After 5 cycles, she developed progressive bilateral lower-extremity paresthesias, sensory loss, areflexia, and distal weakness. Lumbar puncture demonstrated albuminocytologic dissociation, and electromyography confirmed acute inflammatory demyelinating polyneuropathy. Pembrolizumab was discontinued, and the patient received intravenous immunoglobulin with improvement.</div></div><div><h3>Conclusion</h3><div>This case highlights the importance of early recognition of GBS. ICI discontinuation and rapid initiation of treatment are essential to avoid life-threatening complications and optimize patient outcomes.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"60 ","pages":"Article 101816"},"PeriodicalIF":1.3,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144780599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Use of intraoperative ultrasound in resection of early-stage borderline ovarian tumors: A case series 术中超声在早期交界性卵巢肿瘤切除术中的应用:一个病例系列
IF 1.3
Gynecologic Oncology Reports Pub Date : 2025-07-28 DOI: 10.1016/j.gore.2025.101817
Karthiga Natarajan , Marilyn Boo , Samir A. Saidi
{"title":"Use of intraoperative ultrasound in resection of early-stage borderline ovarian tumors: A case series","authors":"Karthiga Natarajan ,&nbsp;Marilyn Boo ,&nbsp;Samir A. Saidi","doi":"10.1016/j.gore.2025.101817","DOIUrl":"10.1016/j.gore.2025.101817","url":null,"abstract":"<div><div>Borderline ovarian tumors (BOTs) commonly occur in women of reproductive age. For patients desiring fertility preservation, cystectomies are recommended as healthy ovarian tissue is spared. However, intraoperative identification of small BOTs can be challenging. Intraoperative ultrasound is a novel technique that enhances the visualization of anatomical structures, potentially allowing for a more precise excision of the ovarian lesion, which maximizes the preservation of healthy ovarian tissue. Although it has clear advantages, the literature on the use of intraoperative ultrasound in gynecological surgeries remains limited.</div><div>Cases: We describe a case series of four women aged between 20 and 33 years old who underwent ultrasound-guided laparoscopic cystectomy for early-stage BOTs.</div><div>Discussion: We demonstrate that intraoperative ultrasound in laparoscopic resection of early-stage BOTs improves visualization of the ovarian tissue, thereby minimizing the amount of healthy ovarian tissue excised, which optimizes fertility preservation in patients.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"61 ","pages":"Article 101817"},"PeriodicalIF":1.3,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144827767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信